Abbott announced that FDA approved the XIENCE V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE V is the only drug eluting stent to have demonstrated superiority over Boston Scientific's TAXUS paclitaxel-eluting coronary stent system

Hansen Medical has received the FDA 510(k) clearance to market the CoHesion 3D visualization module for use in complex electrophysiology mapping procedures.

Neovasc, formerly Medical Ventures, has changed its name and expanded product portfolio, as the company completed the acquisition of two vascular product development companies and the closing of an $8.3 million private financing.

ARYx Therapeutics has announced positive results from cardiac safety study on its prokinetic agent, ATI-7505.

Austria-based Nabriva Therapeutics, which is engaged in the discovery and development of antibacterial agents, has appointed George Golumbeski as CEO of the company.

MedaSorb Technologies has announced the closing of a $4.45 million private placement of its Series B 10% cumulative convertible preferred stock.

Bayer HealthCare has announced that its consumer care division has achieved the necessary regulatory approvals to complete the acquisition of the western over-the-counter cough and cold portfolio of Topsun Science and Technology Qidong Gaitianli Pharmaceutical by Bayer Healthcare Company in

Ethicon, a Johnson & Johnson company, has received an unconditional offer from One Equity Partners to acquire the Professional Wound Care business.

AstraZeneca has announced that the US District Court of New Jersey has granted the company's motion for summary judgment of no inequitable conduct.

Ambulatory Services of America has formed Rosa of Northern Illinois, its fifth joint venture to provide outpatient radiation oncology services.

Intercytex Group has announced the positive six month follow-up data from two Phase II trials of Vavelta, its cell therapy product for damaged skin.

Molina Healthcare has named Glen Bogner as the president of its health plan subsidiary, Molina Healthcare of Washington.

HD Medical has entered into a distribution agreement with BPL for the distribution of the company's first pipeline product, ViScope 100. The distribution agreement is valued at $10 million.

SkyePharma has announced that its third Phase III efficacy study evaluating Flutiform for the treatment of mild to moderate asthma in adolescent and adult patients has met its primary endpoints.

Animas, a Johnson & Johnson company, has received the FDA clearance for its OneTouch Ping glucose management system.

Jerini and Shire have reached a strategic agreement according to which Shire shall be obliged to make a voluntary public takeover offer to all shareholders of Jerini.

Abbott has announced that the FDA approved the Xience V everolimus eluting coronary stent system for the treatment of coronary artery disease.

USHIFU, a provider of non-invasive high intensity focused ultrasound for prostate cancer, has acquired Focus Surgery, a manufacturer of the Sonablate 500, an image-guided acoustic ablation device.

Patheon has completed a shareholders agreement and a sales and marketing agreement with BSP Pharmaceuticals, a company focused on the development and manufacturing of cytotoxic pharmaceutical products.

ARYx Therapeutics has announced that Procter & Gamble Pharmaceuticals has utilized a one-time 30 day cancellation option linked to the completion of a Thorough QT study to end the collaboration agreement between the two companies.